The global emerging sleep apnea devices and platforms market size was valued at USD 6190 million in 2021. It is estimated to reach an expected USD 14476 million by 2030 at a CAGR of 9.9% during the forecast period (2022-2030).
Sleep apnea is "an involuntary cessation of breathing that happens while the patient is asleep," by the American Sleep Apnea Association (ASAA). Obstructive sleep apnea (OSA), central sleep apnea, and mixed or complex sleep apnea are the three subtypes of sleep apnea that can be distinguished. According to the ASAA, OSA is the most prevalent type of sleep apnea. Often, the patient is unaware of their condition as the breathlessness does not cause a full awakening while the patient is asleep. During the forecast period, the global emerging sleep apnea devices and platforms market is expected to be impacted by various growth-promoting and inhibiting factors. For instance, the growing awareness regarding the ill effects of untreated sleep apnea, rising demand for portable sleep apnea devices, and technological advancements in sleep screening and monitoring would propel the market growth.
The prevalence of sleep apnea has been increasing considerably since the 1990s. However, the diagnosis rate of the disease is considerably low. For instance, according to the study conducted by the Canadian Medical Association Journal (CMAJ) titled "Diagnosis and treatment of obstructive sleep apnea in adults" in December 2017, 3%-50% of Canadian adults suffered from sleep apnea; however, only 3% of the Canadians have had the disease clinically diagnosed. Chronic illnesses like cardiovascular diseases, metabolic disorders, cognitive decline, and depression can all be brought on by untreated sleep apnea. Additionally, sleep apnea can raise death rates and the likelihood of car accidents.
To rectify the situation, various regional associations and consortiums, such as the American Sleep Apnea Association (ASAA), Canadian Sleep Society, and Indian Association of Surgeons for Sleep Apnoea have been spreading awareness about sleep apnea. The organizations encourage research in the field of sleep medicines and conduct seminars to bring the patient and physicians on the same platform. The rising awareness about the ill effects of untreated sleep apnea has increased the adoption of various sleep apnea devices, such as home sleep testing devices, actigraphy devices, sleep screening and monitoring devices and solutions, and portable treatment devices, which has propelled the growth of the market.
Several sleep laboratories have trusted developing portable sleep apnea treatment and diagnostic devices. Various sleep apnea devices such as positive airway pressure (PAP) devices, adaptive servo ventilators (ASVs), oral appliances, therapeutic neurostimulators and wearables, home sleep testing devices, pulse oximeters, actigraphy devices, and emerging sleep screening and monitoring solutions are portable in size, facilitating ease of movement and application for the patient. Furthermore, according to the study conducted by NCBI titled "New technology to assess sleep apnea: wearables, smartphones, and accessories" in 2018, portable home sleep testing devices are the leading devices for diagnosing sleep disorders. Moreover, the increasing usage of at-home monitoring devices escalates the clinical diagnosis of severe sleep apnea cases, such as central sleep apnea (CSA) and complex sleep apnea.
For sleep apnea treatment devices, portability ensures prolonged adherence to the therapy. Companies such as ResMed, Koninklijke Philips N.V., and Somnetics International, Inc. have developed portable continuous positive airway pressure (CPAP) devices.
The lack of medical adherence to CPAP therapy is primarily evident in developed economies. For instance, according to a study done by NCBI titled "Barriers to CPAP Use in India: An Exploratory Study in 2017", the adherence rate for CPAP therapy in India was 82.7% (for buyers) and 30.3% (for the Indian population). However, in western countries, the non-adherence rate for CPAP therapy ranges between 46% and 83%. The non-adherence is caused due to various limitations of CPAP therapy, such as mask discomfort, mask leakage, pressure intolerance, skin irritation, nasal congestion, nasal drying, nosebleeds, and claustrophobia. Moreover, the application of CPAP therapy is limited to obstructive sleep apnea. The therapy does not apply to patients with central and complex sleep apnea. Hence, the limited application of CPAP therapy and the high rate of non-adherence has restricted the customer base for sleep apnea treatment and negatively impacted the market's growth.
Owing to the COVID-19 pandemic, the demand for home sleep solutions, including treatment, diagnosis, and monitoring solutions, has significantly increased, especially for elderly sleep apnea patients. Furthermore, the scope of the opportunity encompasses various other laboratory services, such as mask fitting and in-lab titration of PAP devices.
The companies can tap into the opportunity and develop solutions specifically for non-essential laboratory services. For instance, ResMed launched MaskSelector, a digital tool for selecting facial interfaces for sleep apnea therapy in May 2020. The selection is based on the patient's sleeping patterns and facial attributes. The tool is available in the U.S. and is accessible through smart devices. Thus, the homecare segment is the emerging business expansion opportunity for the global emerging apnea devices and platforms market.
By product, the global sleep apnea devices and platforms market is segmented into therapeutic, diagnostic, and monitoring. The therapeutic segment is further divided into positive airway pressure devices, facial interfaces, oral appliances, adaptive-servo ventilators, and emerging therapeutic devices. The diagnostic and monitoring is further divided into polysomnography devices, home sleep testing devices, pulse oximeters, actigraphy devices, sleep screening and monitoring devices and solutions, and emerging sleep screening and monitoring devices and solutions. The therapeutic product type accounted for the largest market share and is estimated to grow at a CAGR of 10.2% during the forecast period. The segment's growth is propelled by the rising demand for portable sleep apnea treatment devices, increasing usage of oral appliances, and technological advancements in the sleep apnea landscape.
The diagnostic and monitoring segment is the second largest. The technological advancements within sleep screening and monitoring devices and solutions and rising demand for home sleep testing devices are the major growth propellers for the segment.
By end user, the global sleep apnea devices and platforms market is segmented into sleep laboratories/hospitals and individuals/ homecare settings. The sleep laboratories/hospitals accounted for the largest market share and is estimated to grow at a CAGR of 8.2% during the forecast period. The sleep laboratories utilize various therapeutic, diagnostic, and monitoring products such as positive airway pressure (PAP) devices, facial interfaces, adaptive servo ventilators (ASVs), polysomnography (PSG) devices, actigraphy devices, and enterprise solutions. The segment's growth is propelled by the increasing prevalence of sleep apnea, favorable reimbursement landscape, and increasing diagnosis of the disease. Moreover, the individuals/homecare settings utilize several therapeutic devices such as PAP devices, facial interfaces, oral appliances, ASVs, home sleep testing devices, pulse oximeters, ambulatory PSG devices, and actigraphy devices. Furthermore, the emerging therapeutic, diagnostic, and monitoring devices and solutions also fall under the individuals and homecare settings segment. The main propeller for the segment's growth is the technological advancement in sleep apnea devices.
The individuals/homecare setting is the second largest. The individuals/homecare setting is the emerging end-user segment of the global emerging sleep apnea devices and platforms market. The segment includes sleep apnea patients and homecare service providers. The homecare centers offer various services such as PAP installations, coaching, and counseling on using PAP devices, follow-ups, and nursing services. The drivers for the segment growth included a limited number of sleep laboratories and a favorable reimbursement scenario. Furthermore, the segment is anticipated to grow significantly in 2020, owing to the COVID-19 pandemic. The segment's primary growth factors are the rising demand for home sleep studies and the minimal risk of infection for elderly sleep apnea patients.
North America dominated the global emerging sleep apnea devices and platforms market and is anticipated to grow at a CAGR of 8.9% during the forecast period. The market is primarily driven by the elevated demand for portable sleep apnea devices, favorable reimbursement landscape, and technological advancements in the sleep apnea landscape. During the COVID-19 pandemic, the market was driven by the regulatory modifications and emergency use authorizations (EUA) provided to the companies. The primary factor propelling the growth of the regional market is the high prevalence of sleep apnea. For instance, according to the study conducted by Lancet on "Estimation of global prevalence and burden of obstructive sleep apnoea: a literature-based analysis in July 2019", approximately 14.5% of the country's population, aged between 30-69 years, suffered from moderate-severe sleep apnea. Furthermore, 33.2% of the same population group suffered from mild sleep apnea, which can become critical if not treated. Furthermore, in Canada, only 4.8% of the population, aged between 30-69 years, suffers from moderate-severe sleep apnea, and only 24.5% suffer from mild sleep apnea.
Europe is the second largest region. It is estimated to reach an expected USD 3695 million at a CAGR of 9.41% during the forecast period. Public reimbursement and the high adoption rate of sleep apnea devices are propelling the growth of the region's market. In Europe, the high prevalence of sleep apnea is the primary factor in market growth. For instance, Lancet's study on the Estimation of global prevalence and burden of obstructive sleep apnoea: a literature-based analysis in July 2019, 3,60,05,318 people aged between 30-69 years suffer from moderate-severe sleep apnea in Europe.
Asia-Pacific is the third largest region. The market's growth is primarily due to the rising prevalence of sleep apnea, increasing diagnosis of the disease, and technologically advanced economies with a high adoption rate of sleep apnea devices. Most of the countries in the Asia-Pacific region are emerging economies. They are undergoing significant technological advancements and improvements in their healthcare systems. The region has been a center for cheap raw materials for medical device manufacturers, including sleep apnea devices. Additionally, increasing healthcare expenditure and improving infrastructure have promoted the growth of the ventilator market within the region at a higher rate. Other factors for the market's growth in the region include a rapid rate of urbanization, an aging population, and a rising number of respiratory and lifestyle-associated diseases, such as sleep apnea, COPD, and asthma.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|